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SHORT COMMUNICATION
Thermochemotherapy-induced resistance to cyclophosphamide
M. Urano, J. Kahn & L.A. Kenton
Edwin L. Steele Radiation Biology Laboratory, Department ofRadiation Medicine, Massachusetts General Hospital, Harvard
Medical School, Boston, MA 02114, USA.
Hyperthermia enhances the cytotoxic effect of some chemo-
therapeutic agents by various mechanisms (Johnson &
Pavelec, 1973; Hahn, 1975). In a series of experiments
studying the effect of cyclophosphamide (CY) at various
temperatures, the effect of two or more treatments was
investigated. It has been demonstrated that administration of
some drugs induces resistance to a subsequent administration
of the drug (Schimke, 1984; Goldie & Coldman, 1984), and
that hyperthermia also induces resistance to some chemo-
therapeutic agents (Morgan et al., 1979; Donaldson et al.,
1978).
Animals were 10 to 12 week old C3Hf/Sed mice derived
from our defined flora mouse colony. They were kept in the
same facility throughout the duration of the experiments.
Sterilized mouse pellets and acidified and vitamin-K fortified
water were provided ad libitum. The early generation iso-
transplants of a fibrosarcoma which arose spontaneously in
a C3Hf/Sed mouse, FSa-II were used. Single cell suspensions
were prepared by a trypsinization procedure and trans-
planted into the foot. Hyperthermia was administered by
immersing the animals' feet into a water bath where desired
temperatures were maintained by a constant temperature
circulator (Lauda, model MS, West Germany) (Urano et al.,
1980). Animals were not anaesthetised for hyperthermia
treatment.
Tumours were treated when they reached an average
diameter of 4mm (35mm3) and the TG (tumour growth)
time, or the time required for a tumour to reach 1000mm3
after the last treatment day, was determined on the tumour-
regrowth curve for each tumour. Then, the median TG time
was calculated for each group by logit analysis (Urano et al.,
1980). Approximately 7 to 10 animals were used for each
datum point and all experiments were repeated at least once.
The test agent was cyclophosphamide (CY) (Mead
Johnson, Syracuse, NY). This agent was selected since its
plasma half-time is longer in comparison with other
alkylating agents (Begg & Smith, 1984). It was dissolved in
distilled water and injected intraperitoneally.
Animals with 4mm FSa-II tumours received one to five
daily treatments of CY alone, combined heat and CY, or
combined glucose, hyperthermia and CY treatments. A CY
dose of 50mgkg-1 each was given i.p. 30min before hyper-
thermia, and a glucose dose of 5mgg-1 each was given
60min before heat treatment. Hyperthermia was at 41.5°C
for 60min, which gives a maximum enhancement for the CY
treatment (Urano et al., 1985). The rationale for the
administration of glucose is given elsewhere (Urano & Kim,
1983). Our previous experiments indicated that hyper-
glycaemia enhances the cytotoxic effect of CY as a result of
reduced tumour tissue pH (Urano et al., 1985; Rhee et al.,
unpublished data).
The dose-response curve for single doses of CY appears to
be exponential, while those for combined treatments are
biphasic or downward concave (solid symbols in Figure 1).
Daily treatments shown by open symbols and dotted lines
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Figure 1 The dose response curves for the TG time of FSa-II
tumours as a function of cyclophosphamide (CY) dose given as a
single dose (solid symbols) or 1 to 5 daily doses of 50mgkg-1
each (open symbols). Top panel shows dose response curves
following CY alone. Middle and bottom panels indicate com-
bined CY and hyperthermia at 41.5°C for 60min, and combined
glucose (5mgg-1), CY, and hyperthermia at 41.5°C for 60min,
respectively. Vertical bars are 95% confidence limit.
were less effective than single doses. The dose response curve
for one to five daily CY doses alone showed a negative
slope, indicating that the FSa-II tumour responded poorly to
doses 2 to 5 and regrew during the treatment period,
although the tumour responded to the 1st CY dose as
evidenced by a prolongation of the TG time from 9.5 days
(no CY) to 11 days (50mgkg-1 CY).
The dose response curves for combined CY and heat, and
for combined glucose, CY, and heat show that these
treatments appeared to have inhibited regrowth during the
treatment period as shown by a flat dose response curve
(middle and bottom panels in Figure 1, respectively). This
also means that an increase in the number of treatments did
not prolong the TG time. Combined glucose, CY and
hyperthermia showed a slightly better response than com-
bined CY and hyperthermia. However, the effect of doses 2
to 5 was negligible compared to the 1st dose.
The second experiment investigated the response to CY, or
combined CY and heat treatments of tumours pretreated
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with CY (100mgkg-1), and/or hyperthermia (60min at
41.50C). FSa-II tumours pretreated with 100mgkg-1 CY
responded poorly to the second CY dose given with a
treatment interval greater than 4h (Figure 2, upper panel,
solid line). This suggests that drug resistance developed
following the first CY administration. The treatment interval
of 4h resulted in a marginally longer TG time compared to
the single dose, but the difference was not significant. Drug
resistance also developed following combined CY and
hyperthermia. The development was similar to that following
treatment with CY alone (Figure 2, top panel, dotted line).
The tumours pretreated with hyperthermia became slightly
resistant to a subsequent administration of CY, but the
difference was not statistically significant (Figure 2, lower
panel, solid line). It should be noted that this hyperthermia
dose of 41.5°C for 60min alone did not prolong the TG
time of the 4mm FSa-II tumour, and hyperthermia given
immediately before CY administration did not enhance the
cytotoxic effect of CY. No significant drug resistance was
observed when hyperthermia alone was followed by
combined CY and heat treatments (Figure 2, lower panel,
dotted line).
To investigate the cross-resistance between hyperthermia
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Figure 3 The effect of a single CY of 200mgkg-1 dose
followed by a subsequent heat treatment at 41.5°C for 60min
with various treatment intervals on the TG time of FSa-II
tumours. The shaded area represents the additive effect of a CY
dose and a heat treatment.
cyclophosphamide, the effect of preadministration of effect of CY given immediately before heat was enhanced by
)phosphamide on the thermal response of the FSa-II hyperthermia and the TG time was prolonged to 25.5 days.
)ur was investigated. A CY dose of 100mgkg 1 was No further enhancement was observed for combined doses
iwed by a heat treatment at 45.5°C for 10min. The with time intervals greater than 1 h. Combined effects given
;ment temperature was increased compared to the with time intervals greater than 1 h were additive. This
,mentioned experiments, since no definite tumour additive effect is shown as the shaded area in Figure 3. This
ith delay was observed following a treatment of 41-.5C means that prior CY administration did not induce resis-
50min. As shown in Figure 3, heat treatment at 45.5°C tance to subsequent hyperthermia nor thermotolerance.
10mmn and a CY dose of 100mgkg- prolonged the TG The mechanisms of chemoresistance and thermotolerance
from 10.5 to 13.5 and to 14.5 days, respectively. The have been extensively studied. The presence of amplified
chromosomes and increased synthesis of heat shock proteins
(HSP) are frequent observations in mammalian cells that
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'CY + H' and 'CY + H' tively. Another interpretation might be that cellular capa-
bility of repairing sublethal damage was increased by the -............ .............. ............j initial CY dose. The present study, together withother
investigations (Morgan et al., 1979; Donaldson et al., 1978;
CY and CY Hazen et al., 1981; Neilan et al., 1986), have shown that the
t-I\ cells pre-treated with CY or combined CY and hyperthermia
_____+____t____t__ became resistant to subsequent administrations of the
chemotherapeutic agent (Figure 2, upper panel, open circles).
The present study suggests that drug-induced resistance is
the main mechanism of the thermochemotherapy resistance.
Some pathophysiological changes induced by the first
H and'CY + H' hyperthermia dose may also contribute to the development
............ ........... ...................... . of this resistance. It is likely that hyperthermia reduced the
blood flow in the tumour, resulting in inhibition of drug
uptake. Cells pretreated with heat showed an insignificant
level of resistance to CY, and cells pretreated with CY were
H and CY not resistant to subsequent hyperthermia. This evidence
indicates a lack of cross-resistance between heat and drug.
Present fractionation studies demonstrated that the
resistance established by administration of CY or combined
CY and hyperthermia treatments to subsequent treatments
was consistent throughout the fractionated treatments. The
0 12 24 36 48 magnitude ot the resistance was not moitmiea oy two to iive
identical treatments.
Hours between 2treatments The development of drug-resistance is critical for clinical
cancer therapy. Studies on the mechanism and the kinetics of
ure 2 The effect of single CY of 100mgkg-I (upper panel) drug resistance as well as the establishment of a method to
; cirlt-, hint tro§tint at A1 f° f. min , vp mni-h ,n overcome its development are urgently needed.
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the effect of subsequent administration of 100mgkg-I CY given
alone or in combination of hyperthermia. The effect of combined
CY and hyperthermia on the subsequent combined treatments is
also shown in the top panel (open circles). Vertical bars show
95% confidence limit.
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